Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2007

01.05.2007

Treatment Failure After Percutaneous Radiofrequency Ablation for Nonsurgical Candidates With Pulmonary Metastases From Colorectal Carcinoma

verfasst von: Tristan D. Yan, BSc (Med), MBBS, Julie King, MPH, Adrian Sjarif, BSc (Med), MBBS, Derek Glenn, MBBS, Karin Steinke, MD, Ahmed Al-Kindy, MD, David L. Morris, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

This study critically evaluated the local and overall treatment failure rates after percutaneous radiofrequency ablation (RFA) of pulmonary metastases from colorectal carcinoma.

Methods

Fifty-five nonsurgical candidates underwent RFA of colorectal pulmonary metastases. The primary end points of this study were local progression-free survival (PFS) and overall PFS. Univariate and multivariate analyses were performed to identify significant prognostic parameters for local and overall PFS.

Results

The local recurrence rate was 38%. For local PFS, univariate analysis demonstrated that the largest size of lung metastasis, the location of lung metastases, the post-RFA carcinoembryonic antigen level at 1 month, and the post-RFA carcinoembryonic antigen level at 3 months were significant prognostic indicators. In multivariate analysis, a largest size of lung metastasis of >3 cm and a post-RFA carcinoembryonic antigen level of >5 ng/mL at 1 month were independently associated with a reduced local PFS. The overall recurrence rate was 66%. For overall PFS, univariate analysis demonstrated that sex and the largest size of lung metastasis were significant prognostic indicators. In multivariate analysis, a largest size of lung metastasis of >3 cm was independently associated with a reduced overall PFS.

Conclusions

RFA of colorectal pulmonary metastases may have a useful role in local disease control for nonsurgical candidates, but its efficacy in patients with a lung metastasis of >3 cm is limited.
Literatur
1.
Zurück zum Zitat Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analysis based on 5206 cases. J Thorac Cardiovasc Surg 1997; 113:37–49CrossRef Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analysis based on 5206 cases. J Thorac Cardiovasc Surg 1997; 113:37–49CrossRef
2.
Zurück zum Zitat Okumura S, Kondo H, Tsuboi M, et al. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996; 112:867–74PubMedCrossRef Okumura S, Kondo H, Tsuboi M, et al. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996; 112:867–74PubMedCrossRef
3.
Zurück zum Zitat van Halteren HK, van Geel AN, Hart AA, et al. Pulmonary resection for metastases of colorectal origin. Chest 1995;107:1525–31 van Halteren HK, van Geel AN, Hart AA, et al. Pulmonary resection for metastases of colorectal origin. Chest 1995;107:1525–31
4.
Zurück zum Zitat Brister SJ, de Varennes B, Gordon PH, et al. Contemporary operative management of pulmonary metastases of colorectal origin. Dis Colon Rectum 1998; 31:786–92CrossRef Brister SJ, de Varennes B, Gordon PH, et al. Contemporary operative management of pulmonary metastases of colorectal origin. Dis Colon Rectum 1998; 31:786–92CrossRef
5.
Zurück zum Zitat Sakamoto T, Tsubota N, Iwanaga K, et al. Pulmonary resection for metastases from colorectal cancer. Chest 2001; 119:1069–72PubMedCrossRef Sakamoto T, Tsubota N, Iwanaga K, et al. Pulmonary resection for metastases from colorectal cancer. Chest 2001; 119:1069–72PubMedCrossRef
6.
Zurück zum Zitat Morrow CE, Vassilopoulos PP, Grage TB. Surgical resection for metastatic neoplasms of the lung: experience at the University of Minnesota Hospitals. Cancer 1980; 45:2981–5PubMedCrossRef Morrow CE, Vassilopoulos PP, Grage TB. Surgical resection for metastatic neoplasms of the lung: experience at the University of Minnesota Hospitals. Cancer 1980; 45:2981–5PubMedCrossRef
7.
Zurück zum Zitat McCormack PM, Burt ME, Bains MS, et al. Lung resection for colorectal metastases. 10-year results. Arch Surg 1992; 127:1403–6PubMed McCormack PM, Burt ME, Bains MS, et al. Lung resection for colorectal metastases. 10-year results. Arch Surg 1992; 127:1403–6PubMed
8.
Zurück zum Zitat Rusch VW. Pulmonary metastasectomy. Current indications. Chest 1995; 107:322S–331SPubMed Rusch VW. Pulmonary metastasectomy. Current indications. Chest 1995; 107:322S–331SPubMed
9.
Zurück zum Zitat Watanabe I, Arai T, Ono M, et al. Prognostic factors in resection of pulmonary metastasis from colorectal cancer. Br J Surg 2003; 90:1436–40PubMedCrossRef Watanabe I, Arai T, Ono M, et al. Prognostic factors in resection of pulmonary metastasis from colorectal cancer. Br J Surg 2003; 90:1436–40PubMedCrossRef
10.
Zurück zum Zitat Pfannschmidt J, Muley T, Hoffmann H, et al. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experienced in 167 patients. J Thorac Cardiovasc Surg 2003; 126:732–9PubMedCrossRef Pfannschmidt J, Muley T, Hoffmann H, et al. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experienced in 167 patients. J Thorac Cardiovasc Surg 2003; 126:732–9PubMedCrossRef
11.
Zurück zum Zitat Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124:1007–13PubMedCrossRef Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124:1007–13PubMedCrossRef
12.
Zurück zum Zitat Rena O, Casadio C, Viano F, et al. Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. Eur J Cardiothorac Surg 2002; 21:906–12PubMedCrossRef Rena O, Casadio C, Viano F, et al. Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. Eur J Cardiothorac Surg 2002; 21:906–12PubMedCrossRef
13.
Zurück zum Zitat Colucci G, Gebbin V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005; 23:4866–75PubMedCrossRef Colucci G, Gebbin V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005; 23:4866–75PubMedCrossRef
14.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRef Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRef
15.
Zurück zum Zitat Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059–69PubMedCrossRef Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059–69PubMedCrossRef
16.
Zurück zum Zitat de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47PubMed de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47PubMed
17.
Zurück zum Zitat Douillard J-Y, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000; 355:1041–7PubMedCrossRef Douillard J-Y, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000; 355:1041–7PubMedCrossRef
18.
Zurück zum Zitat Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136–47PubMed Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136–47PubMed
19.
Zurück zum Zitat Steinke K, Glenn D, King J, et al. Percutaneous imaging-guided radiofrequency ablation in patients with colorectal pulmonary metastases: 1-year follow-up. Ann Surg Oncol 2004; 11:207–12PubMedCrossRef Steinke K, Glenn D, King J, et al. Percutaneous imaging-guided radiofrequency ablation in patients with colorectal pulmonary metastases: 1-year follow-up. Ann Surg Oncol 2004; 11:207–12PubMedCrossRef
20.
Zurück zum Zitat King J, Glenn D, Clark W, et al. Percutaneous radiofrequency ablation of pulmonary metastases in patients with colorectal cancer. Br J Surg 2004; 91:217–23PubMedCrossRef King J, Glenn D, Clark W, et al. Percutaneous radiofrequency ablation of pulmonary metastases in patients with colorectal cancer. Br J Surg 2004; 91:217–23PubMedCrossRef
21.
Zurück zum Zitat Steinke K, Sewell PE, Dupuy D, et al. Pulmonary radiofrequency ablation—an international study survey. Anticancer Res 2004; 24:339–43PubMed Steinke K, Sewell PE, Dupuy D, et al. Pulmonary radiofrequency ablation—an international study survey. Anticancer Res 2004; 24:339–43PubMed
22.
Zurück zum Zitat Dupuy DE, DiPetrillo T, Gandhi S, et al. Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest 2006; 129:738–45PubMedCrossRef Dupuy DE, DiPetrillo T, Gandhi S, et al. Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest 2006; 129:738–45PubMedCrossRef
23.
Zurück zum Zitat Lee J, Jin GY, Goldberg SN, et al. Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report. Radiology 2004; 230:125–34PubMedCrossRef Lee J, Jin GY, Goldberg SN, et al. Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report. Radiology 2004; 230:125–34PubMedCrossRef
24.
Zurück zum Zitat Fernando HC, De Hoyos A, Landreneau RJ, et al. Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg 2005; 129:639–44PubMedCrossRef Fernando HC, De Hoyos A, Landreneau RJ, et al. Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg 2005; 129:639–44PubMedCrossRef
25.
Zurück zum Zitat Herrera LJ, Fernando HC, Perry Y, et al. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg 2003; 125:929–37PubMedCrossRef Herrera LJ, Fernando HC, Perry Y, et al. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg 2003; 125:929–37PubMedCrossRef
26.
Zurück zum Zitat Suh R, Reckamp K, Zeidler M, et al. Radiofrequency ablation in lung cancer: promising results in safety and efficacy. Oncology 2005; 19:12–21PubMed Suh R, Reckamp K, Zeidler M, et al. Radiofrequency ablation in lung cancer: promising results in safety and efficacy. Oncology 2005; 19:12–21PubMed
27.
Zurück zum Zitat Steinke K, Glenn D, King J, et al. Percutaneous pulmonary radiofrequency ablation: difficulty achieving complete ablations in big lung lesions. Br J Radiol 2003; 76:742–5PubMedCrossRef Steinke K, Glenn D, King J, et al. Percutaneous pulmonary radiofrequency ablation: difficulty achieving complete ablations in big lung lesions. Br J Radiol 2003; 76:742–5PubMedCrossRef
28.
Zurück zum Zitat Ambrogi MC, Lucchi M, Dini P, et al. Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. Eur J Cardiothorac Surg 2006; 30:177–83PubMedCrossRef Ambrogi MC, Lucchi M, Dini P, et al. Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. Eur J Cardiothorac Surg 2006; 30:177–83PubMedCrossRef
29.
Zurück zum Zitat Akeboshi M, Yamakado K, Nakatsuka A, et al. Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. J Vasc Interv Radiol 2004; 15:463–70PubMed Akeboshi M, Yamakado K, Nakatsuka A, et al. Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. J Vasc Interv Radiol 2004; 15:463–70PubMed
30.
Zurück zum Zitat Goldberg SN, Gazelle GS, Compton CC, et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. Acad Radiol 1995; 2:776–84PubMedCrossRef Goldberg SN, Gazelle GS, Compton CC, et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. Acad Radiol 1995; 2:776–84PubMedCrossRef
31.
Zurück zum Zitat Dupuy DE, Mayo-Smith WW, DiPettrillo T, et al. Clinical experience of pulmonary radiofrequency ablation in 27 patients (abstract 389). Radiological Society of North America Proceedings, Chicago, November 2001 Dupuy DE, Mayo-Smith WW, DiPettrillo T, et al. Clinical experience of pulmonary radiofrequency ablation in 27 patients (abstract 389). Radiological Society of North America Proceedings, Chicago, November 2001
32.
Zurück zum Zitat Vaughn C, Mychaskiw G II, Sewell P. Massive hemorrhage during radiofrequency ablation of a pulmonary neoplasm. Anesth Analg 2002; 94:1149–51PubMedCrossRef Vaughn C, Mychaskiw G II, Sewell P. Massive hemorrhage during radiofrequency ablation of a pulmonary neoplasm. Anesth Analg 2002; 94:1149–51PubMedCrossRef
33.
Zurück zum Zitat Avital I, DeMatteo R. Combined resection of liver and lung metastases for colorectal cancer. Thorac Surg Clin 2006; 16:145–55PubMedCrossRef Avital I, DeMatteo R. Combined resection of liver and lung metastases for colorectal cancer. Thorac Surg Clin 2006; 16:145–55PubMedCrossRef
Metadaten
Titel
Treatment Failure After Percutaneous Radiofrequency Ablation for Nonsurgical Candidates With Pulmonary Metastases From Colorectal Carcinoma
verfasst von
Tristan D. Yan, BSc (Med), MBBS
Julie King, MPH
Adrian Sjarif, BSc (Med), MBBS
Derek Glenn, MBBS
Karin Steinke, MD
Ahmed Al-Kindy, MD
David L. Morris, MD, PhD
Publikationsdatum
01.05.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9271-x

Weitere Artikel der Ausgabe 5/2007

Annals of Surgical Oncology 5/2007 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.